There are 30 resources available
1O - Inducible T cell co-stimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and combination with pembrolizumab: Preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC)
Presenter: Christophe Le Tourneau
Session: Proffered Papers 1: Immunotherapy
Resources:
Abstract
5P - Association between baseline tumor size and outcome in patients treated with next-generation immunoncology agents
Presenter: Paolo Tarantino
Session: Poster Display & Cocktail
Resources:
Abstract
6P - Targeting leukemic stem cells using humanized chimeric immunotoxin
Presenter: Madhumathi Jayaprakasam
Session: Poster Display & Cocktail
Resources:
Abstract
10P - In vitro and in vivo cytolethal and antitumor effects of a novel fusion protein targeting IL-24 toward breast cancer cells
Presenter: Ali Jahanian-Najafabadi
Session: Poster Display & Cocktail
Resources:
Abstract
7P - Proteomics plus RNA-seq in advanced melanoma samples treated with anti-PD1 immunotherapy unravel resistance mechanisms
Presenter: Guillermo Prado
Session: Poster Display & Cocktail
Resources:
Abstract
11P - Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
Presenter: Eric Angevin
Session: Poster Display & Cocktail
Resources:
Abstract
12P - IL-18 improves the anti-cancer immunity of human gamma delta T cells against prostate cancer
Presenter: Mohanad Nada
Session: Poster Display & Cocktail
Resources:
Abstract
13P - A mitigation of breast cancer-induced immune-suppressive tumor microenvironment through curbing miR-155/IL-10/TNF-α loop using a novel quercetin derivative
Presenter: Rana Youness
Session: Poster Display & Cocktail
Resources:
Abstract
14P - Comparison of the predictive power of survival of the Royal Marsden Score, the GRIM score and the LIPI score in phase I trial patients
Presenter: Eduardo Castanon Alvarez
Session: Poster Display & Cocktail
Resources:
Abstract
20P - Interim safety and efficacy results of a phase II clinical trial on trametinib and low-dose dabrafenib in patients with advanced BRAFV600 wild-type melanoma
Presenter: Gil Awada
Session: Poster Display & Cocktail
Resources:
Abstract